JP5931336B2 - がんを処置および診断するための組成物および方法 - Google Patents

がんを処置および診断するための組成物および方法 Download PDF

Info

Publication number
JP5931336B2
JP5931336B2 JP2010514866A JP2010514866A JP5931336B2 JP 5931336 B2 JP5931336 B2 JP 5931336B2 JP 2010514866 A JP2010514866 A JP 2010514866A JP 2010514866 A JP2010514866 A JP 2010514866A JP 5931336 B2 JP5931336 B2 JP 5931336B2
Authority
JP
Japan
Prior art keywords
antibody
protein
cancer
human
lgr5
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2010514866A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010532169A5 (enExample
JP2010532169A (ja
Inventor
オースティン ガーニー
オースティン ガーニー
Original Assignee
オンコメッド ファーマシューティカルズ インコーポレイテッド
オンコメッド ファーマシューティカルズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40226729&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5931336(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by オンコメッド ファーマシューティカルズ インコーポレイテッド, オンコメッド ファーマシューティカルズ インコーポレイテッド filed Critical オンコメッド ファーマシューティカルズ インコーポレイテッド
Publication of JP2010532169A publication Critical patent/JP2010532169A/ja
Publication of JP2010532169A5 publication Critical patent/JP2010532169A5/ja
Application granted granted Critical
Publication of JP5931336B2 publication Critical patent/JP5931336B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2010514866A 2007-07-02 2008-07-02 がんを処置および診断するための組成物および方法 Active JP5931336B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94761107P 2007-07-02 2007-07-02
US60/947,611 2007-07-02
PCT/US2008/008210 WO2009005809A2 (en) 2007-07-02 2008-07-02 Compositions and methods for treating and diagnosing cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014103056A Division JP2014144016A (ja) 2007-07-02 2014-05-19 がんを処置および診断するための組成物および方法

Publications (3)

Publication Number Publication Date
JP2010532169A JP2010532169A (ja) 2010-10-07
JP2010532169A5 JP2010532169A5 (enExample) 2012-07-26
JP5931336B2 true JP5931336B2 (ja) 2016-06-08

Family

ID=40226729

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2010514866A Active JP5931336B2 (ja) 2007-07-02 2008-07-02 がんを処置および診断するための組成物および方法
JP2014103056A Withdrawn JP2014144016A (ja) 2007-07-02 2014-05-19 がんを処置および診断するための組成物および方法
JP2016148170A Pending JP2016187356A (ja) 2007-07-02 2016-07-28 がんを処置および診断するための組成物および方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2014103056A Withdrawn JP2014144016A (ja) 2007-07-02 2014-05-19 がんを処置および診断するための組成物および方法
JP2016148170A Pending JP2016187356A (ja) 2007-07-02 2016-07-28 がんを処置および診断するための組成物および方法

Country Status (14)

Country Link
US (10) US8158758B2 (enExample)
EP (3) EP3009148B1 (enExample)
JP (3) JP5931336B2 (enExample)
AU (1) AU2008270972B2 (enExample)
CA (1) CA2691378A1 (enExample)
CY (1) CY1116967T1 (enExample)
DK (1) DK2173379T3 (enExample)
ES (2) ES2694018T3 (enExample)
HR (1) HRP20151261T1 (enExample)
HU (1) HUE027154T2 (enExample)
PL (2) PL3009148T3 (enExample)
PT (1) PT2173379E (enExample)
SI (1) SI2173379T1 (enExample)
WO (1) WO2009005809A2 (enExample)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2093298A3 (en) 2003-10-10 2009-09-23 Deutsches Krebsforschungszentrum Compositions for diagnosis and therapy of diseases associated with aberrant expression of Futrins (R-Spondins)
MX2009003726A (es) 2006-10-20 2009-04-22 Deutsches Krebsforsch R-espondinas como moduladores de la angiogenesis y vasculogenesis.
HUE027154T2 (en) 2007-07-02 2016-08-29 Oncomed Pharm Inc Preparations and procedures for the treatment and diagnosis of cancer
JP5676107B2 (ja) 2007-11-14 2015-02-25 中外製薬株式会社 抗ｇｐｒ４９抗体を用いる癌の診断および治療
WO2010016766A2 (en) * 2008-08-08 2010-02-11 Koninklijke Nederlandse Akademie Van Wetenschappen Antibodies recognizing endogenous human lgr5 and/or lgr6
US8652843B2 (en) 2008-08-12 2014-02-18 Oncomed Pharmaceuticals, Inc. DDR1-binding agents and methods of use thereof
US20110171650A1 (en) * 2008-09-16 2011-07-14 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Gene expression related to preeclampsia
US9752124B2 (en) 2009-02-03 2017-09-05 Koninklijke Nederlandse Akademie Van Wetenschappen Culture medium for epithelial stem cells and organoids comprising the stem cells
EP2412800A1 (en) 2010-07-29 2012-02-01 Koninklijke Nederlandse Akademie van Wetenschappen Liver organoid, uses thereof and culture method for obtaining them
HUE062459T2 (hu) 2009-02-03 2023-11-28 Koninklijke Nederlandse Akademie Van Wetenschappen Tenyésztõközeg epiteliális õssejtek és az epiteliális õssejteket tartalmazó organoidok részére
US8563307B2 (en) 2009-02-24 2013-10-22 James Wang Treatment of immunosuppression-related disorders
US8389689B2 (en) * 2009-10-28 2013-03-05 Janssen Biotech, Inc. Anti-GLP-1R antibodies and their uses
CN102821600B (zh) 2009-12-25 2016-01-20 中外制药株式会社 使用移植了nog确立癌细胞株的非人动物模型进行的抗癌药靶探索以及筛选方法
US8679474B2 (en) 2010-08-04 2014-03-25 StemBios Technologies, Inc. Somatic stem cells
EP2626414B1 (en) 2010-10-06 2020-07-15 Chugai Seiyaku Kabushiki Kaisha Cancer stem cell mass and process for production thereof
GB201106395D0 (en) 2011-04-14 2011-06-01 Hubrecht Inst Compounds
US9057096B2 (en) 2011-05-20 2015-06-16 Board Of Regents Of The University Of Texas System Regulation of Wnt/beta-catenin signaling
AU2013204484B2 (en) * 2011-07-15 2016-05-12 Oncomed Pharmaceuticals, Inc. RSPO binding agents and uses thereof
EP2731625B1 (en) * 2011-07-15 2018-04-18 OncoMed Pharmaceuticals, Inc. Rspo binding agents and uses thereof
WO2013035824A1 (ja) 2011-09-07 2013-03-14 ファーマロジカルズ・リサーチ プライベート リミテッド 癌幹細胞の分離
TWI571513B (zh) 2011-09-28 2017-02-21 幹細胞生物科技股份有限公司 體幹細胞及其製備方法
CN109111523B (zh) 2011-10-14 2022-06-07 诺华股份有限公司 用于Wnt途径相关疾病的抗体和方法
US20140302511A1 (en) 2011-10-28 2014-10-09 Pharmalogicals Research Pte. Ltd. Cancer stem cell-specific molecule
WO2013067055A1 (en) * 2011-11-01 2013-05-10 Bionomics, Inc. Methods of blocking cancer stem cell growth
CN104053671A (zh) 2011-11-01 2014-09-17 生态学有限公司 治疗癌症的抗体和方法
WO2013067057A1 (en) * 2011-11-01 2013-05-10 Bionomics, Inc. Anti-gpr49 antibodies
WO2013067060A1 (en) * 2011-11-01 2013-05-10 Bionomics, Inc. Anti-gpr49 antibodies
US9352039B2 (en) 2012-02-09 2016-05-31 The Regents Of The University Of Michigan Method of reducing the number of EMT and MET type breast cancer stem cells
RU2014133069A (ru) 2012-02-11 2016-04-10 Дженентек, Инк. Транслокации r-спондина и способы с их использованием
AR090549A1 (es) * 2012-03-30 2014-11-19 Genentech Inc Anticuerpos anti-lgr5 e inmunoconjugados
US20140017721A1 (en) * 2012-07-13 2014-01-16 The Research Foundation Of State University Of New York Spontaneously immortalized prostate cancer cell line
AU2013289990B2 (en) * 2012-07-13 2018-06-14 Oncomed Pharmaceuticals, Inc. RSPO3 binding agents and uses thereof
CN104822827B (zh) 2012-12-06 2020-01-21 干细胞生物科技公司 Lgr5+体干细胞
EP2746769A1 (en) 2012-12-21 2014-06-25 Stembios Technologies, Inc. Method for evaluating effect of action on subject based on stem celldynamics
WO2014192974A1 (ja) 2013-05-30 2014-12-04 株式会社オーダーメードメディカルリサーチ 抗ｌｇｒ６抗体を含む癌の検出用又は診断用試薬
KR20160055252A (ko) 2013-09-17 2016-05-17 제넨테크, 인크. 항-lgr5 항체의 사용 방법
WO2015108203A1 (ja) 2014-01-15 2015-07-23 株式会社オーダーメードメディカルリサーチ 抗ｓｌｃ６ａ６抗体を用いたがん治療用医薬組成物
ES2833599T3 (es) 2014-02-28 2021-06-15 Merus Nv Anticuerpo que se une a ERBB-2 y ERBB-3
NZ724013A (en) 2014-02-28 2019-11-29 Merus Nv Antibodies that bind egfr and erbb3
AU2015240599B2 (en) 2014-04-04 2020-11-19 Bionomics, Inc. Humanized antibodies that bind LGR5
EP3524572A1 (en) * 2014-05-05 2019-08-14 Synexis LLC Air permeable substrate structure
WO2015191715A1 (en) 2014-06-11 2015-12-17 Genentech, Inc. Anti-lgr5 antibodies and uses thereof
JP2017528523A (ja) * 2014-09-16 2017-09-28 オンコメッド ファーマシューティカルズ インコーポレイテッド 線維性疾患の治療
WO2016057629A1 (en) * 2014-10-07 2016-04-14 Duke University Methods and therapeutics relating to human r-spondin protein and leucine-rich repeat-containing g protein-coupled receptor protein
MA41123A (fr) * 2014-12-02 2017-10-10 Oncomed Pharm Inc Polythérapie pour le traitement du cancer
WO2017040660A1 (en) * 2015-08-31 2017-03-09 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of disease
SG11201803359VA (en) 2015-10-23 2018-05-30 Merus Nv Binding molecules that inhibit cancer growth
CN105274061A (zh) * 2015-10-26 2016-01-27 无锡傲锐东源生物科技有限公司 抗lgr5蛋白单克隆抗体杂交瘤细胞及其产生的抗lgr5单克隆抗体和应用
EP3432925A4 (en) 2016-03-22 2019-11-06 Bionomics Limited ADMINISTRATION OF A MONOCLONAL ANTI-LGR5 ANTIBODY
US11655304B2 (en) 2016-09-16 2023-05-23 Bionomics Limited Antibody and checkpoint inhibitor combination therapy
EP3548515A1 (en) 2016-12-01 2019-10-09 Regeneron Pharmaceuticals, Inc. Radiolabeled anti-pd-l1 antibodies for immuno-pet imaging
JP7737220B2 (ja) 2017-03-31 2025-09-10 メルス ナムローゼ フェンノートシャップ ＮＲＧ１融合遺伝子を有する細胞の処置における使用のためのＥｒｂＢ－２及びＥｒｂＢ３結合二重特異性抗体
MX2019013804A (es) 2017-05-17 2020-02-24 Merus Nv Combinacion de un anticuerpo biespecifico de erbb-2/erbb-3 con terapia endocrina para cancer de mama.
DK3665198T3 (da) 2017-08-09 2025-04-28 Merus Nv Antistoffer, der binder egfr og cmet
WO2021123198A1 (en) * 2019-12-19 2021-06-24 Deutsches Krebsforschungszentrum Leukemia treatment
US20230338466A1 (en) * 2020-06-03 2023-10-26 Children's Hospital Medical Center Compositions and methods comprising r-spondins for treatment of tumors

Family Cites Families (136)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4109496A (en) 1977-12-20 1978-08-29 Norris Industries Trapped key mechanism
US4323546A (en) 1978-05-22 1982-04-06 Nuc Med Inc. Method and composition for cancer detection in humans
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US4981785A (en) 1988-06-06 1991-01-01 Ventrex Laboratories, Inc. Apparatus and method for performing immunoassays
US4968103A (en) 1988-07-22 1990-11-06 Photofinish Cosmetics Inc. Method of making a brush
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8901778D0 (en) 1989-01-27 1989-03-15 Univ Court Of The University O Manipulatory technique
US5028205A (en) 1989-12-14 1991-07-02 Ingersoll-Rand Company Oil scavenger system for a seal for a rotary shaft
US5614396A (en) 1990-06-14 1997-03-25 Baylor College Of Medicine Methods for the genetic modification of endogenous genes in animal cells by homologous recombination
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DK0564531T3 (da) 1990-12-03 1998-09-28 Genentech Inc Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
EP0552108B1 (en) 1992-01-17 1999-11-10 Lakowicz, Joseph R. Energy transfer phase-modulation fluoro-immunoassay
US5376313A (en) 1992-03-27 1994-12-27 Abbott Laboratories Injection molding a plastic assay cuvette having low birefringence
US20070124581A1 (en) 1992-05-17 2007-05-31 Reena Khare Cell adhesion and extracellular matrix proteins
EP0672131B1 (en) 1992-10-30 2003-12-17 The General Hospital Corporation A novel cell cycle control protein
AU6045094A (en) 1993-02-19 1994-09-14 Nippon Shinyaku Co. Ltd. Drug composition containing nucleic acid copolymer
US5639606A (en) 1993-04-06 1997-06-17 The University Of Rochester Method for quantitative measurement of gene expression using multiplex competitive reverse transcriptase-polymerase chain reaction
US5876978A (en) 1993-04-06 1999-03-02 Medical College Of Ohio Method for quantitative measurement of gene expression using multiplex competitive reverse transcriptase-polymerase chain reaction
US5643765A (en) 1993-04-06 1997-07-01 University Of Rochester Method for quantitative measurement of gene expression using multiplex competitive reverse transcriptase-polymerase chain reaction
US5538848A (en) 1994-11-16 1996-07-23 Applied Biosystems Division, Perkin-Elmer Corp. Method for detecting nucleic acid amplification using self-quenching fluorescence probe
US5599677A (en) 1993-12-29 1997-02-04 Abbott Laboratories Immunoassays for prostate specific antigen
US5807522A (en) 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
WO1997023782A1 (en) 1995-12-22 1997-07-03 Abbott Laboratories Fluorescence polarization immunoassay diagnostic method
US5994316A (en) 1996-02-21 1999-11-30 The Immune Response Corporation Method of preparing polynucleotide-carrier complexes for delivery to cells
US5885529A (en) 1996-06-28 1999-03-23 Dpc Cirrus, Inc. Automated immunoassay analyzer
JP2002500753A (ja) 1997-03-07 2002-01-08 クレア ケミカル リサーチ エルエルシー 可視光を用いた蛍光検出
US6080912A (en) 1997-03-20 2000-06-27 Wisconsin Alumni Research Foundation Methods for creating transgenic animals
CA2288343A1 (en) 1997-04-25 1998-11-05 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
US6004528A (en) 1997-09-18 1999-12-21 Bergstein; Ivan Methods of cancer diagnosis and therapy targeted against the cancer stemline
US6083616A (en) 1997-09-19 2000-07-04 Seal Products, Inc. Nontack pressure activated adhesive
EP1017811A4 (en) * 1997-09-24 2002-08-14 Merck & Co Inc HG38 GLYCOPROTEIN HORMONE RECEPTOR COUPLED WITH G-PROTEIN
US20020065394A1 (en) 1998-03-18 2002-05-30 Kenneth Jacobs Secreted proteins and polynucleotides encoding them
ES2332025T3 (es) 1998-03-26 2010-01-22 The Board Of Trustees Of The Leland Stanford Junior University Nuevos receptores de mamiferos acoplados a la proteina g que tienen regiones extracelulares de repeticion ricas en leucina.
US6485972B1 (en) 1998-10-15 2002-11-26 President And Fellows Of Harvard College WNT signalling in reproductive organs
WO2001088088A2 (en) 2000-05-18 2001-11-22 Hyseq, Inc. Novel nucleic acids and polypeptides
US20030166047A1 (en) 1999-05-06 2003-09-04 Millennium Pharmaceuticals, Inc. Lgr6 nucleic acids and uses thereof
CA2378403A1 (en) 1999-07-26 2001-02-01 Genentech, Inc. Novel polynucleotides and method for the use thereof
US6824973B2 (en) 2000-02-03 2004-11-30 Kirin Beer Kabushiki Kaisha Method of promoting stem cell proliferation or survival by contacting a cell with a stem cell factor-like polypeptide
CA2399776A1 (en) 2000-02-03 2001-08-09 Hyseq, Inc. Novel nucleic acids and polypeptides
AU2001253012B2 (en) 2000-03-31 2006-02-23 The General Hospital Corporation Methods of modulating hair growth
AU5904101A (en) 2000-04-05 2001-10-23 Hyseq Inc Methods and materials relating to novel stem cell growth factor-like polypeptides and polynucleotides
EP1156062A1 (en) * 2000-05-12 2001-11-21 GPC Biotech AG Immunomodulatory human MHC class II antigen-binding peptides/proteins
EP1290030A2 (en) 2000-05-30 2003-03-12 Bayer Aktiengesellschaft Regulation of human lgr4-like g protein-coupled receptor
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US6768004B2 (en) 2001-01-11 2004-07-27 Mueller Sybille Nucleotide sequences encoding variable regions of heavy and light chains of monoclonal antibody 1F7, an anti-idiotypic antibody reactive with anti-HIV antibodies
US20040077048A1 (en) 2002-01-30 2004-04-22 Warren Bridget A. Protein modification and maintenance molecules
US20030032034A1 (en) 2001-03-05 2003-02-13 Tang Y. Tom Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides
US7411052B2 (en) 2001-03-05 2008-08-12 Nuvelo, Inc. Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides
US20100292155A1 (en) 2001-03-05 2010-11-18 Arca Biopharma, Inc. Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides
AU2002304249A1 (en) 2001-06-11 2002-12-23 Kirin Beer Kabushiki Kaisha Polypeptide having an activity to support proliferation or survival of hematopoietic stem cell and hematopoietic progenitor cell, and dna coding for the same
EP1423428B2 (en) * 2001-06-20 2012-11-14 Fibron Ltd. Antibodies that block fgfr3 activation, methods of screening for and uses thereof
US20030022217A1 (en) 2001-07-02 2003-01-30 Pe Corporation (Ny) Isolated human secreted proteins, nucleic acid molecules encoding human secreted proteins, and uses thereof
EP2228443A1 (en) 2001-08-30 2010-09-15 ARCA biopharma, Inc. Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides
AU2002342010A1 (en) 2001-10-03 2003-04-14 Incyte Genomics Inc. Secreted proteins
US20070237770A1 (en) 2001-11-30 2007-10-11 Albert Lai Novel compositions and methods in cancer
US20040197778A1 (en) 2002-12-26 2004-10-07 Sagres Discovery, Inc. Novel compositions and methods in cancer
EP1461023A4 (en) 2001-12-07 2005-08-31 Univ Michigan Prospective Identification and Characterization of Breast Cancer Strain Cells
CA2469941A1 (en) 2001-12-10 2003-07-03 Nuvelo, Inc. Novel nucleic acids and polypeptides
US7193069B2 (en) 2002-03-22 2007-03-20 Research Association For Biotechnology Full-length cDNA
AU2003223124A1 (en) 2002-04-26 2003-11-10 Kirin Beer Kabushiki Kaisha Polypeptide having an activity to support proliferation or survival of hematopoietic stem cell or hematopoietic progenitor cell, and dna coding for the same
EP1380644A1 (en) 2002-07-08 2004-01-14 Kylix B.V. The use of specified TCF target genes to identify drugs for the treatment of cancer, in particular colorectal cancer, in which TCF/beta-catenin/WNT signalling plays a central role
AU2003303459A1 (en) * 2002-12-26 2004-07-22 Applied Research Systems Ars Holding N.V. Spliced variants of lgr6
WO2004074436A2 (en) * 2003-02-19 2004-09-02 Incyte Corporation Methods of use of a gpcr in the diagnosis and treatment of colon and lung cancer
US20050003405A1 (en) 2003-04-30 2005-01-06 Hua-Chien Chen Treatment and diagnostics of cancer
CA2528669A1 (en) 2003-06-09 2005-01-20 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US20050054829A1 (en) 2003-07-22 2005-03-10 Wiley Steven R. Compositions and methods relating to TSP-30a, b, c and d
DE10339820A1 (de) * 2003-08-22 2005-03-17 Hinzmann, Bernd, Dr. Verwendung von an GPR49 bindenden Substanzen zur Diagnose und Behandlung von Krebs
US9046537B2 (en) 2003-09-22 2015-06-02 Enzo Biochem, Inc. Method for treating inflammation by administering a compound which binds LDL-receptor-related protein (LRP) ligand binding domain
EP2093298A3 (en) 2003-10-10 2009-09-23 Deutsches Krebsforschungszentrum Compositions for diagnosis and therapy of diseases associated with aberrant expression of Futrins (R-Spondins)
WO2005040828A2 (en) 2003-10-24 2005-05-06 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 49 (gpr49)
US20050256036A1 (en) 2004-01-27 2005-11-17 Boyle Bryan J Gastrointestinal proliferative factor and uses thereof
CA2554779A1 (en) * 2004-02-03 2005-08-18 The Regents Of The University Of Michigan Compositions and methods for characterizing, regulating, diagnosing, and treating cancer
US7572456B2 (en) 2004-09-13 2009-08-11 Macrogenics, Inc. Humanized antibodies against West Nile Virus and therapeutic and prophylactic uses thereof
AU2005318171B2 (en) 2004-12-20 2011-09-29 Crucell Holland B.V. Binding molecules capable of neutralizing West Nile virus and uses thereof
US7439327B2 (en) 2005-01-18 2008-10-21 Nuvelo, Inc. Stem cell factor-like proteins and uses thereof
EP1871911A2 (en) 2005-04-07 2008-01-02 Chiron Corporation Cancer-related genes (prlr)
US20090036369A1 (en) 2005-07-26 2009-02-05 Kirin Pharma Kabushiki Kaisha Anti-tumor agents comprising r-spondins
US7541431B2 (en) * 2005-09-07 2009-06-02 Maine Medical Center Cristin/R-spondin ligands active in the Wnt signaling pathway and methods, compositions and kits relating thereto
EP1942926A4 (en) 2005-10-07 2010-06-16 Nuvelo Inc STEM CELL FACTOR ARTIFICIAL PROTEIN SCFA1 AND ITS USES
WO2007053648A2 (en) * 2005-10-31 2007-05-10 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US7723477B2 (en) * 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
GB0603683D0 (en) * 2006-02-23 2006-04-05 Novartis Ag Organic compounds
US7659378B2 (en) 2006-06-02 2010-02-09 Aveo Pharmaceuticals, Inc. Hepatocyte growth factor (HGF) binding antibody
CA2654025C (en) 2006-06-02 2016-08-02 Xoma Technology Ltd. Hepatocyte growth factor (hgf) binding proteins
ES2413087T3 (es) 2006-06-13 2013-07-15 Oncomed Pharmaceuticals, Inc. Composiciones y métodos para el diagnóstico y tratamiento del cáncer
US8460667B2 (en) 2006-07-18 2013-06-11 Sanofi EPHA2 receptor antagonist antibodies
JP2008044926A (ja) * 2006-08-14 2008-02-28 Trustees Of Columbia Univ In The City Of New York Ｗｎｔ信号伝達に関係した分泌タンパク質
ME02371B (me) 2006-09-29 2016-06-20 Oncomed Pharm Inc Sastojci i postupci za dijagnstikovanje i tretman raka
MX2009003726A (es) 2006-10-20 2009-04-22 Deutsches Krebsforsch R-espondinas como moduladores de la angiogenesis y vasculogenesis.
WO2008075796A1 (ja) 2006-12-21 2008-06-26 Kyowa Hakko Kirin Co., Ltd. 血球回復促進剤
WO2008088524A2 (en) * 2006-12-28 2008-07-24 Nuvelo, Inc. Thrombospondin-domain-deficient r-spondin 1 protein as gastrointestinal tract epithelial proliferation factor
BRPI0812562A2 (pt) 2007-06-12 2019-09-24 Trubion Pharmaceuticals Inc composições terapêuticas anti-cd20 e métodos
HUE027154T2 (en) 2007-07-02 2016-08-29 Oncomed Pharm Inc Preparations and procedures for the treatment and diagnosis of cancer
US20120082659A1 (en) 2007-10-02 2012-04-05 Hartmut Land Methods And Compositions Related To Synergistic Responses To Oncogenic Mutations
WO2009045443A2 (en) 2007-10-02 2009-04-09 The University Of Rochester Methods and compositions related to synergistic responses to oncogenic mutations
JP5676107B2 (ja) 2007-11-14 2015-02-25 中外製薬株式会社 抗ｇｐｒ４９抗体を用いる癌の診断および治療
US8187601B2 (en) 2008-07-01 2012-05-29 Aveo Pharmaceuticals, Inc. Fibroblast growth factor receptor 3 (FGFR3) binding proteins
WO2010016766A2 (en) 2008-08-08 2010-02-11 Koninklijke Nederlandse Akademie Van Wetenschappen Antibodies recognizing endogenous human lgr5 and/or lgr6
CN103408664B (zh) 2008-10-31 2015-11-25 东丽株式会社 抗人cxcl1单克隆抗体或其片段
EP2419133A1 (en) 2009-04-15 2012-02-22 Deutsches Krebsforschungszentrum Rspondin-3 inhibition in bone disorders
WO2010129284A1 (en) 2009-04-27 2010-11-11 The Trustees Of The University Of Pennsylvania Inhibition of hair follicle growth by the wnt inhibitor dkk1
AU2010245011B2 (en) 2009-04-27 2015-09-03 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
CN102695499A (zh) 2009-06-18 2012-09-26 惠氏有限责任公司 小模块免疫药物的冻干制剂
US8318162B2 (en) 2009-07-16 2012-11-27 Xoma Technology Ltd. Antibodies to high molecular weight melanoma associated antigen
CN103951753B (zh) 2009-09-03 2018-01-12 默沙东公司 抗‑gitr抗体
WO2011076932A1 (en) 2009-12-23 2011-06-30 Deutsches Krebsforschungszentrum Receptors of rspo2 and rspo3
WO2011085289A1 (en) 2010-01-11 2011-07-14 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University Production of a monoclonal antibody therapeutic against west nile virus in plants
WO2011140441A2 (en) 2010-05-06 2011-11-10 Children's Hospital Medical Center Methods and systems for converting precursor cells into intestinal tissues through directed differentiation
EP2659005A4 (en) 2010-12-28 2016-08-24 Caris Mpi Inc MOLECULAR PROFILING OF CANCER
GB201106395D0 (en) 2011-04-14 2011-06-01 Hubrecht Inst Compounds
KR101873614B1 (ko) 2011-04-28 2018-07-02 에스비아이 바이오테크 가부시키가이샤 항인간 수용체형 단백질 티로신 포스파타아제 σ 항체
EP2731625B1 (en) 2011-07-15 2018-04-18 OncoMed Pharmaceuticals, Inc. Rspo binding agents and uses thereof
CN109111523B (zh) 2011-10-14 2022-06-07 诺华股份有限公司 用于Wnt途径相关疾病的抗体和方法
WO2013067057A1 (en) 2011-11-01 2013-05-10 Bionomics, Inc. Anti-gpr49 antibodies
WO2013067055A1 (en) 2011-11-01 2013-05-10 Bionomics, Inc. Methods of blocking cancer stem cell growth
RU2014133069A (ru) 2012-02-11 2016-04-10 Дженентек, Инк. Транслокации r-спондина и способы с их использованием
AR090549A1 (es) 2012-03-30 2014-11-19 Genentech Inc Anticuerpos anti-lgr5 e inmunoconjugados
AU2013289990B2 (en) 2012-07-13 2018-06-14 Oncomed Pharmaceuticals, Inc. RSPO3 binding agents and uses thereof
EP2968348A4 (en) 2013-03-12 2016-11-09 Curegenix Inc COMPOUNDS FOR THE TREATMENT OF CANCER
WO2014192974A1 (ja) 2013-05-30 2014-12-04 株式会社オーダーメードメディカルリサーチ 抗ｌｇｒ６抗体を含む癌の検出用又は診断用試薬
BR112016008477A2 (pt) 2013-10-18 2017-10-03 Genentech Inc Corpos, ácido nucleico, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica e usos do anticorpo
MA41123A (fr) 2014-12-02 2017-10-10 Oncomed Pharm Inc Polythérapie pour le traitement du cancer
US9777052B2 (en) 2014-12-02 2017-10-03 The Board Of Regents Of The University Of Oklahoma R-spondin variants, compositions, and methods of use

Also Published As

Publication number Publication date
WO2009005809A2 (en) 2009-01-08
CA2691378A1 (en) 2009-01-08
EP3424529A1 (en) 2019-01-09
HRP20151261T1 (hr) 2016-01-01
US8628774B2 (en) 2014-01-14
US20150165024A1 (en) 2015-06-18
JP2016187356A (ja) 2016-11-04
EP3009148B1 (en) 2018-08-22
DK2173379T3 (en) 2015-12-07
US20090074782A1 (en) 2009-03-19
US20170296658A1 (en) 2017-10-19
US9610348B2 (en) 2017-04-04
US9717794B2 (en) 2017-08-01
HUE027154T2 (en) 2016-08-29
US20130115206A1 (en) 2013-05-09
US8540989B2 (en) 2013-09-24
US20090191205A1 (en) 2009-07-30
US8883736B2 (en) 2014-11-11
US9040044B2 (en) 2015-05-26
SI2173379T1 (sl) 2015-12-31
US20130121993A1 (en) 2013-05-16
PL3009148T3 (pl) 2019-03-29
PT2173379E (pt) 2015-11-24
AU2008270972B2 (en) 2013-10-24
US20140134177A1 (en) 2014-05-15
WO2009005809A3 (en) 2009-04-02
US8158757B2 (en) 2012-04-17
PL2173379T3 (pl) 2016-02-29
US8158758B2 (en) 2012-04-17
US20130336970A1 (en) 2013-12-19
AU2008270972A1 (en) 2009-01-08
ES2694018T3 (es) 2018-12-17
ES2553169T5 (es) 2023-11-30
JP2010532169A (ja) 2010-10-07
EP2173379B2 (en) 2023-07-05
CY1116967T1 (el) 2017-04-05
EP2173379B1 (en) 2015-09-02
EP3009148A1 (en) 2016-04-20
US20150337050A1 (en) 2015-11-26
JP2014144016A (ja) 2014-08-14
EP2173379A2 (en) 2010-04-14
ES2553169T3 (es) 2015-12-04
US20180099047A1 (en) 2018-04-12

Similar Documents

Publication Publication Date Title
JP5931336B2 (ja) がんを処置および診断するための組成物および方法
US8501472B2 (en) Compositions and methods for treating and diagnosing pancreatic cancer
WO2009009114A2 (en) Compositions and methods for treating and diagnosing cancer
CN112740043A (zh) Vista受体
AU2013203352B2 (en) Compositions and methods for treating and diagnosing cancer
WO2009111644A2 (en) Compositions and methods for diagnosing and treating pancreatic cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110701

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110701

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20120201

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20120201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20120201

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20120201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120606

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130328

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130627

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130704

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130729

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20130729

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140120

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140519

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20140526

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20140620

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20151015

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151026

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20151026

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160204

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160427

R150 Certificate of patent or registration of utility model

Ref document number: 5931336

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250